NASDAQ:MTFBMOTIF BIO PLC/S Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding MOTIF BIO PLC/S Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Share Today's Range N/A50-Day Range$0.11MA: $0.11▼$0.1152-Week Range N/AVolume867,698 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis. Motif Bio plc was incorporated in 2014 and is based in New York, New York.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingMOTIF BIO PLC/S has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, MOTIF BIO PLC/S has a potential upside of ∞ from its current price of $0.00.Amount of Analyst CoverageMOTIF BIO PLC/S has received no research coverage in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesMOTIF BIO PLC/S has received 240 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMOTIF BIO PLC/S has received 275 “underperform” votes. (Add your “underperform” vote.)Community SentimentMOTIF BIO PLC/S has received 53.40% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about MOTIF BIO PLC/S and other stocks. Vote “Outperform” if you believe MTFB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MTFB will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMOTIF BIO PLC/S does not currently pay a dividend.Dividend GrowthMOTIF BIO PLC/S does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MOTIF BIO PLC/S insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for MOTIF BIO PLC/S are expected to grow in the coming year, from ($1.60) to ($1.35) per share. Previous Next Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.29 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MTFB Previous Symbol CUSIPN/A CIK1674657 Webwww.motifbio.com Phone212-210-6248Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.60) per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees7 Outstanding Shares14,830,000Market CapN/A Next Earnings DateN/A OptionableNot Optionable NASDAQ:MTFB Rates by TradingView Receive MTFB News and Ratings via Email Sign-up to receive the latest news and ratings for MTFB and its competitors with MarketBeat's FREE daily newsletter. MOTIF BIO PLC/S (NASDAQ:MTFB) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of MOTIF BIO PLC/S? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MOTIF BIO PLC/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for MOTIF BIO PLC/S. What price target have analysts set for MTFB? 1 analysts have issued 12-month price targets for MOTIF BIO PLC/S's shares. Their forecasts range from $5.00 to $5.00. On average, they anticipate MOTIF BIO PLC/S's share price to reach $5.00 in the next year. View analysts' price targets for MOTIF BIO PLC/S. Has MOTIF BIO PLC/S been receiving favorable news coverage? Media coverage about MTFB stock has been trending very negative recently, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. MOTIF BIO PLC/S earned a coverage optimism score of -3.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutMOTIF BIO PLC/S. Who are some of MOTIF BIO PLC/S's key competitors? Some companies that are related to MOTIF BIO PLC/S include Aeolus Pharmaceuticals (AOLS), Affymax (AFFY), American Oriental Bioengineering (AOBI), Aoxing Pharmaceutical (AOXG), Bohai Pharmaceuticals Group (BOPH), Epirus Biopharmaceuticals (EPRSQ), ERBA Diagnostics (ERBA), FutureWorld (FWDG), GlobeImmune (GBIM), Myrexis (MYRX), NeuroVive Pharmaceutical (NEVPF), Newron Pharmaceuticals (NWPHF), Pivot Pharmaceuticals (PVOTF), Pivotal Therapeutics (PVTTF) and Poniard Pharmaceuticals (PARD). View all competitors. What other stocks do shareholders of MOTIF BIO PLC/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other MOTIF BIO PLC/S investors own include Sorrento Therapeutics (SRNE), Allergan (AGN), Ampliphi Biosciences (APHB), Neurocrine Biosciences (NBIX), Canopy Growth (CGC), Forward Pharma A/S (FWP), Novartis (NVS), SDX Energy (SDX), Adaptimmune Therapeutics (ADAP) and Allena Pharmaceuticals (ALNA). Who are MOTIF BIO PLC/S's key executives? MOTIF BIO PLC/S's management team includes the following people: Dr. Graham George Lumsden, CEO & Exec. Director (Age 59)Mr. Jonathan E. Gold, CFO & Exec. Director (Age 46)Dr. David B. Huang, Chief Medical Officer (Age 44)Mr. Robert Dickey IV, Advisor (Age 63)Laurie Doyle, Head of Investor Relations & Corp. Communications When did MOTIF BIO PLC/S IPO? (MTFB) raised $17 million in an initial public offering (IPO) on Friday, November 18th 2016. The company issued 2,400,000 shares at a price of $6.98 per share. H.C. Wainwright & Co. acted as the underwriter for the IPO. What is MOTIF BIO PLC/S's stock symbol? MOTIF BIO PLC/S trades on the NASDAQ under the ticker symbol "MTFB." How do I buy shares of MOTIF BIO PLC/S? Shares of MTFB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. How big of a company is MOTIF BIO PLC/S? MOTIF BIO PLC/S has a market capitalization of $0.00. MOTIF BIO PLC/S employs 7 workers across the globe. What is MOTIF BIO PLC/S's official website? The official website for MOTIF BIO PLC/S is www.motifbio.com. How can I contact MOTIF BIO PLC/S? MOTIF BIO PLC/S's mailing address is 201 TEMPLE CHAMBERS 3-7 TEMPLE AVENUE, LONDON X0, EC4Y0DT. The company can be reached via phone at 212-210-6248 or via email at [email protected] This page was last updated on 5/28/2020 by MarketBeat.com Staff
